In Brief: Myeloid-derived suppressor cells in cancer

26Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The role of myeloid-derived suppressor cells (MDSCs) in cancer development has become clear over recent years, and MDSC targeting is an emerging opportunity for enhancing the effectiveness of current anticancer therapies. As MDSCs are not only able to limit anti-tumour T-cell responses, but also to promote tumour angiogenesis and invasion, their monitoring has prognostic and predictive value. Herein, we review the key features of MDSCs in cancer promotion. © 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Cite

CITATION STYLE

APA

Solito, S., Pinton, L., & Mandruzzato, S. (2017). In Brief: Myeloid-derived suppressor cells in cancer. Journal of Pathology, 242(1), 7–9. https://doi.org/10.1002/path.4876

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free